{"schema_version":"secwatch.filing_event.v1","accession":"0001326732-24-000030","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.870997+00:00","generated_at":"2026-06-02T05:06:51.028867+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Xencor Q1 2024 net loss $68.0M ($1.11/share); revenue down to $12.8M from $19.0M","bullets":["Net loss widened to $68.0M from $60.8M YoY; diluted EPS -$1.11 vs -$1.02.","Revenue fell to $12.8M from $19.0M; non-cash royalty revenue vs prior milestone revenue.","Cash and marketable securities $646.7M at March 31, down from $697.4M at year-end 2023.","First patient dosed in Phase 1 for XmAb541 (CLDN6 x CD3) in solid tumors.","Appointed Bart Cornelissen as new CFO; expects cash runway into 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001326732-24-000030","json":"https://secwatch.observer/filing/0001326732-24-000030.json","markdown":"https://secwatch.observer/filing/0001326732-24-000030.md","text":"https://secwatch.observer/filing/0001326732-24-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000132673224000030/0001326732-24-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000132673224000030/xncr-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:06:51.028867+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f337ced0df8ff67a83939c993448b477cb9839d","claim":"Xencor Inc reported the first quarter ended March 31, 2024 results: revenue $12.8 million, net income $68.0 million, or $(1.11) on a fully diluted per share basis, EPS $(1.11) on a fully diluted per share basis.","evidence_excerpt":"marketable debt securities totaled $646.7 million as of March 31, 2024, compared to $697.4 million on December 31, 2023. Revenues for the first quarter ended March 31, 2024 were $12.8 million, compared to $19.0 million for the same period in 2023. Total revenues earned in the first quarter of 2024 included non-cash royalty revenue from Xencor’s Alexion and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326732/000132673224000030/0001326732-24-000030-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$12.8 million"},{"label":"Net income","value":"$68.0 million, or $(1.11) on a fully diluted per share basis"},{"label":"EPS","value":"$(1.11) on a fully diluted per share basis"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}